Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus

What Was Tested

The paper reports a study of Relaxin (Serelaxin), published as a randomized controlled trial.

Relaxin, an insulin-like peptide hormone, is a candidate to be involved in the underlying molecular mechanisms.

Therefore, the present study investigated the correlation of relaxin expression with fibrinogen levels in diabetes patients undergoing oral antidiabetic treatment.

Who Took Part

According to the abstract, 192 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

In total, 192 type 2 diabetes patients were enrolled into the study.

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the Relaxin (Serelaxin) group and the comparison group should start out alike.

Blood was drawn at baseline and at the end of the study to measure the concentrations of relaxin and fibrinogen with an enzyme-linked immunosorbent assay and a turbimetric method, respectively.

In addition, platelets were counted at both time points.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Enzyme-Linked Immunosorbent Assay, Fibrinogen, Hypoglycemic Agents, Nephelometry and Turbidimetry, Pioglitazone and Relaxin.

What This Means in Plain Language

The paper is a randomized study of Relaxin (Serelaxin) in 192 patients.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology), a journal based in England.

More context: the Relaxin (Serelaxin) compound page, all human trials.